Scoring of late gadolinium enhancement in cardiac magnetic resonance imaging can predict cardiac events in patients with hypertrophic cardiomyopathy

Journal of Cardiology

Volumn 58, Issue 3, 2011, Pages 253-260

  Nojiri, Ayumi ^a   Hongo, Kenichi ^a   Kawai, Makoto ^a   Komukai, Kimiaki ^a   Sakuma, Toru ^a   Taniguchi, Ikuo ^a   Yoshimura, Michihiro ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Family history; Heart failure; Left ventricular hypertrophy; Myocardial fibrosis; Ventricular arrhythmia

Indexed keywords

GADOLINIUM PENTETATE;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MAGNETIC RESONANCE; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; FEMALE; HEART FAILURE; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; LATE GADOLINIUM ENHANCEMENT SCORE; MALE; PREDICTION; RETROSPECTIVE STUDY; SCORING SYSTEM;

AGED; CARDIOMYOPATHY, HYPERTROPHIC; FEMALE; FIBROSIS; FOLLOW-UP STUDIES; FORECASTING; GADOLINIUM; HEART FAILURE; HUMANS; IMAGE ENHANCEMENT; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MYOCARDIUM; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; TACHYCARDIA, VENTRICULAR;

EID: 82855178740     PISSN: 09145087     EISSN: 18764738     Source Type: Journal    
DOI: 10.1016/j.jjcc.2011.07.007     Document Type: Article

References (31)

1. Gosse P. Left ventricular hypertrophy as a predictor of cardiovascular risk. J Hypertens 2005, 23:S27-S33.
2. Gradman A.H., Alfayoumi F. From left ventricular hypertrophy to congestive heart failure: management of hypertensive heart disease. Prog Cardiovasc Dis 2006, 48:326-341.
3. Mahrholdt H., Wagner A., Judd R.M., Sechtem U., Kim R.J. Delayed enhancement cardiovascular magnetic resonance assessment of non-ischaemic cardiomyopathies. Eur Heart J 2005, 26:1461-1474.
4. Rudolph A., Abdel-Aty H., Bohl S., Boyé P., Zagrosek A., Dietz R., Schulz-Menger J. Noninvasive detection of fibrosis applying contrast-enhanced cardiac magnetic resonance in different forms of left ventricular hypertrophy relation to remodeling. J Am Coll Cardiol 2009, 53:284-291.
5. Basso C., Thiene G., Corrado D., Buja G., Melacini P., Nava A. Hypertrophic cardiomyopathy and sudden death in the young: pathologic evidence of myocardial ischemia. Hum Pathol 2000, 31:988-998.
6. Moon J.C., McKenna W.J., McCrohon J.A., Elliott P.M., Smith G.C., Pennell D.J. Toward clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance. J Am Coll Cardiol 2003, 41:1561-1567.
7. Teraoka K., Hirano M., Ookubo H., Sasaki K., Katsuyama H., Amino M., Abe Y., Yamashina A. Delayed contrast enhancement of MRI in hypertrophic cardiomyopathy. Magn Reson Imaging 2004, 22:155-161.
8. Spirito P., Bellone P., Harris K.M., Bernabo P., Bruzzi P., Maron B.J. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med 2000, 342:1778-1785.
9. Maron B.J. Hypertrophic cardiomyopathy: a systematic review. JAMA 2002, 287:1308-1320.
10. Oka K., Tsujino T., Nakao S., Lee-Kawabata M., Ezumi A., Masai M., Ohyanagi M., Masuyama T. Symptomatic ventricular tachyarrhythmia is associated with delayed gadolinium enhancement in cardiac magnetic resonance imaging and with elevated plasma brain natriuretic peptide level in hypertrophic cardiomyopathy. J Cardiol 2008, 52:146-153.
11. Hayato K., Okawa M., Matsumura Y., Kitaoka H., Kubo T., Hitomi N., Yamasaki N., Yabe T., Furuno T., Takata J., Nishinaga M., Doi Y.L. Hypertrophic cardiomyopathy with mild left ventricular remodeling: echocardiographic assessment using left ventricular wall motion score. J Cardiol 2008, 51:95-105.
12. Kwon D.H., Setser R.M., Popović Z.B., Thamilarasan M., Sola S., Schoenhagen P., Garcia M.J., Flamm S.D., Lever H.M., Desai M.Y. Association of myocardial fibrosis, electrocardiography and ventricular tachyarrhythmia in hypertrophic cardiomyopathy: a delayed contrast enhanced MRI study. Int J Cardiovasc Imaging 2008, 24:617-625.
13. O'Hanlon R., Grasso A., Roughton M., Moon J.C., Clark S., Wage R., Webb J., Kulkarni M., Dawson D., Sulaibeekh L., Chandrasekaran B., Bucciarelli-Ducci C., Pasquale F., Cowie M.R., McKenna W.J., et al. Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy. J Am Coll Cardiol 2010, 56:867-874.
14. Bruder O., Wagner A., Jensen C.J., Schneider S., Ong P., Kispert E.M., Nassenstein K., Schlosser T., Sabin G.V., Sechtem U., Mahrholdt H. Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2010, 56:875-887.
15. Spiewak M., Malek L.A., Misko J., Chojnowska L., Milosz B., Klopotowski M., Petryka J., Dabrowski M., Kepka C., Ruzyllo W. Comparison of different quantification methods of late gadolinium enhancement in patients with hypertrophic cardiomyopathy. Eur J Radiol 2010, 74:e149-e153.
16. Harrigan C.J., Peters D.C., Gibson C.M., Maron B.J., Manning W.J., Maron M.S., Appelbaum E. Hypertrophic cardiomyopathy: quantification of late gadolinium enhancement with contrast-enhanced cardiovascular MR imaging. Radiology 2011, 258:128-133.
17. Richardson P., McKenna W., Bristow M., Maisch B., Mautner B., O'Connell J., Olsen E., Thiene G., Goodwin J., Gyarfas I., Martin I., Nordet P. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the definition and classification of cardiomyopathies. Circulation 1996, 93:841-842.
18. Maron B.J., Gottdiener J.S., Epstein S.E. Patterns and significance of distribution of left ventricular hypertrophy in hypertrophic cardiomyopathy. A wide angle, two dimensional echocardiographic study of 125 patients. Am J Cardiol 1981, 48:418-428.
19. Maron M.S., Maron B.J., Harrigan C., Buros J., Gibson C.M., Olivotto I., Biller L., Lesser J.R., Udelson J.E., Manning W.J., Appelbaum E. Hypertrophic cardiomyopathy phenotype revisited after 50 years with cardiovascular magnetic resonance. J Am Coll Cardiol 2009, 54:220-228.
20. Cerqueira M.D., Weissman N.J., Dilsizian V., Jacobs A.K., Kaul S., Laskey W.K., Pennell D.J., Rumberger J.A., Ryan T., Verani M.S. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart: a statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation 2002, 105:539-542. American Heart Association Writing Group on Myocardial Segmentation and Registration for Cardiac Imaging.
21. Choudhury L., Mahrholdt H., Wagner A., Choi K.M., Elliott M.D., Klocke F.J., Bonow R.O., Judd R.M., Kim R.J. Myocardial scarring in asymptomatic or mildly symptomatic patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2002, 40:2156-2164.
22. Kim R.J., Judd R.M. Gadolinium-enhanced magnetic resonance imaging in hypertrophic cardiomyopathy: in vivo imaging of the pathologic substrate for premature cardiac death?. J Am Coll Cardiol 2003, 41:1568-1572.
23. Fieno D.S., Kim R.J., Chen E.L., Lomasney J.W., Klocke F.J., Judd R.M. Contrast-enhanced magnetic resonance imaging of myocardium at risk: distinction between reversible and irreversible injury throughout infarct healing. J Am Coll Cardiol 2000, 36:1985-1991.
24. Moon J.C., Reed E., Sheppard M.N., Elkington A.G., Ho S.Y., Burke M., Petrou M., Pennell D.J. The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol 2004, 43:2260-2264.
25. Kwon D.H., Smedira N.G., Rodriguez E.R., Tan C., Setser R., Thamilarasan M., Lytle B.W., Lever H.M., Desai M.Y. Cardiac magnetic resonance detection of myocardial scarring in hypertrophic cardiomyopathy: correlation with histopathology and prevalence of ventricular tachycardia. J Am Coll Cardiol 2009, 54:242-249.
26. Harris K.M., Spirito P., Maron M.S., Zenovich A.G., Formisano F., Lesser J.R., Mackey-Bojack S., Manning W.J., Udelson J.E., Maron B.J. Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy. Circulation 2006, 114:216-225.
27. Matoh F., Satoh H., Shiraki K., Saitoh T., Urushida T., Katoh H., Takehara Y., Sakahara H., Hayashi H. Usefulness of delayed enhancement magnetic resonance imaging to differentiate dilated phase of hypertrophic cardiomyopathy and dilated cardiomyopathy. J Card Fail 2007, 13:372-379.
28. Adabag A.S., Maron B.J., Appelbaum E., Harrigan C.J., Buros J.L., Gibson C.M., Lesser J.R., Hanna C.A., Udelson J.E., Manning W.J., Maron M.S. Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance. J Am Coll Cardiol 2008, 51:1369-1374.
29. Choi D.S., Ha J.W., Choi B., Yang W.I., Choi E.Y., Rim S.J., Chung N. Extent of late gadolinium enhancement in cardiovascular magnetic resonance and its relation with left ventricular diastolic function in patients with hypertrophic cardiomyopathy. Circ J 2008, 72:1449-1453.
30. Motoyasu M., Kurita T., Onishi K., Uemura S., Tanigawa T., Okinaka T., Takeda K., Nakano T., Ito M., Sakuma H. Correlation between late gadolinium enhancement and diastolic function in hypertrophic cardiomyopathy assessed by magnetic resonance imaging. Circ J 2008, 72:378-383.
31. Saito M., Okayama H., Yoshii T., Hiasa G., Sumimoto T., Inaba S., Nishimura K., Inoue K., Ogimoto A., Shigematsu Y., Funada J., Hamada M., Higaki J. Myocardial fibrosis attenuates the effect of cibenzoline on left ventricular diastolic function in patients with hypertrophic cardiomyopathy. J Cardiovasc Pharmacol 2011, 57:207-212.